Literature DB >> 29243058

Does prophylactic ondansetron reduce norepinephrine consumption in patients undergoing cesarean section with spinal anesthesia?

Feride Karacaer1, Ebru Biricik2, İlker Ünal3, Selim Büyükkurt4, Hakkı Ünlügenç2.   

Abstract

PURPOSE: Spinal anesthesia-induced hypotension (SAIH) during cesarean delivery is not rare and frequently leads to materno-fetal discrepancy and collapse. More recently, norepinephrine has been proposed for the prevention and treatment of SAIH with fewer tendencies to decrease heart rate and cardiac output. Ondansetron has been reported to reduce the incidence of SAIH in patients undergoing cesarean section. The aim of the present study was to assess the effect of prophylactic ondansetron on the incidence of SAIH, norepinephrine consumption, and adverse effects.
METHODS: We recruited 108 parturients with uncomplicated pregnancies undergoing elective cesarean delivery under spinal anesthesia. The parturients were divided into two groups randomly. The first group (n = 54) received 8 mg ondansetron IV (group O) and the second group (n = 54) received the same volume (4 ml) of saline (group S), 5 min before spinal anesthesia. The incidence of hypotension, cumulative episodes of hypotension, total norepinephrine consumption, and adverse effects were recorded.
RESULTS: There was no significant difference between the two groups in demographic data, parturient characteristics, and duration of surgery. No significant difference was found in the incidence of hypotension in the saline and ondansetron groups (p = 0.767). However, the cumulative episodes of hypotension and norepinephrine consumptions were significantly greater in group S than in group O (p = 0.009) (p = 0.009). There was also no significant difference in the incidence of adverse effects between the two groups.
CONCLUSION: Eight milligrams of intravenous ondansetron given 5 min before spinal anesthesia attenuated but did not prevent spinal anesthesia-induced hypotension in parturients undergoing elective cesarean delivery.

Entities:  

Keywords:  Cesarean delivery; Hypotension; Norepinephrine; Ondansetron; Spinal anesthesia

Mesh:

Substances:

Year:  2017        PMID: 29243058     DOI: 10.1007/s00540-017-2436-x

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  20 in total

1.  Intravenous ondansetron causing severe bradycardia: two cases.

Authors:  Nisha Afonso; Amit Dang; Viraj Namshikar; Sahish Kamat; Padmanabh V Rataboli
Journal:  Ann Card Anaesth       Date:  2009 Jul-Dec

2.  Ondansetron Does Not Attenuate Hemodynamic Changes in Patients Undergoing Elective Cesarean Delivery Using Subarachnoid Anesthesia: A Double-Blind, Placebo-Controlled, Randomized Trial.

Authors:  Abdullah S Terkawi; Mohamed Tiouririne; Sachin H Mehta; Jordan M Hackworth; Siny Tsang; Marcel E Durieux
Journal:  Reg Anesth Pain Med       Date:  2015 Jul-Aug       Impact factor: 6.288

3.  The effect of intravenous ondansetron on maternal haemodynamics during elective caesarean delivery under spinal anaesthesia: a double-blind, randomised, placebo-controlled trial.

Authors:  J R Ortiz-Gómez; F J Palacio-Abizanda; F Morillas-Ramirez; I Fornet-Ruiz; A Lorenzo-Jiménez; M L Bermejo-Albares
Journal:  Int J Obstet Anesth       Date:  2014-02-04       Impact factor: 2.603

4.  Phenylephrine infusions during cesarean section under spinal anesthesia.

Authors:  Allison J Lee; Richard M Smiley
Journal:  Int Anesthesiol Clin       Date:  2014

5.  Norepinephrine Intermittent Intravenous Boluses to Prevent Hypotension During Spinal Anesthesia for Cesarean Delivery: A Sequential Allocation Dose-Finding Study.

Authors:  Desire N Onwochei; Warwick D Ngan Kee; Lillia Fung; Kristi Downey; Xiang Y Ye; Jose C A Carvalho
Journal:  Anesth Analg       Date:  2017-07       Impact factor: 5.108

Review 6.  Prevention of Spinal Anesthesia-Induced Hypotension During Cesarean Delivery by 5-Hydroxytryptamine-3 Receptor Antagonists: A Systematic Review and Meta-analysis and Meta-regression.

Authors:  Michael Heesen; Markus Klimek; Sanne E Hoeks; Rolf Rossaint
Journal:  Anesth Analg       Date:  2016-10       Impact factor: 5.108

7.  Ondansetron given intravenously attenuates arterial blood pressure drop due to spinal anesthesia: a double-blind, placebo-controlled study.

Authors:  Radoslaw Owczuk; Wojciech Wenski; Agnieszka Polak-Krzeminska; Pawel Twardowski; Renata Arszułowicz; Anna Dylczyk-Sommer; Magdalena A Wujtewicz; Wioletta Sawicka; Ewa Morzuch; Maciej Smietanski; Maria Wujtewicz
Journal:  Reg Anesth Pain Med       Date:  2008 Jul-Aug       Impact factor: 6.288

8.  Ephedrine versus ondansetron in the prevention of hypotension during cesarean delivery: a randomized, double-blind, placebo-controlled trial.

Authors:  P Nivatpumin; V Thamvittayakul
Journal:  Int J Obstet Anesth       Date:  2016-02-21       Impact factor: 2.603

9.  Continuous invasive blood pressure and cardiac output monitoring during cesarean delivery: a randomized, double-blind comparison of low-dose versus high-dose spinal anesthesia with intravenous phenylephrine or placebo infusion.

Authors:  Eldrid Langesaeter; Leiv Arne Rosseland; Audun Stubhaug
Journal:  Anesthesiology       Date:  2008-11       Impact factor: 7.892

10.  Symptomatic sinus bradycardia: A rare adverse effect of intravenous ondansetron.

Authors:  Md Shahnawaz Moazzam; Farah Nasreen; Shahjahan Bano; Syed Hussain Amir
Journal:  Saudi J Anaesth       Date:  2011-01
View more
  3 in total

1.  Do fetuses need vasopressors just before their birth?

Authors:  Hiroyuki Sumikura
Journal:  J Anesth       Date:  2018-06-21       Impact factor: 2.078

Review 2.  Vasopressors for the Treatment and Prophylaxis of Spinal Induced Hypotension during Caesarean Section.

Authors:  Ebru Biricik; Hakkı Ünlügenç
Journal:  Turk J Anaesthesiol Reanim       Date:  2020-05-05

3.  Does an Earlier or Late Intravenous Injection of Ondansetron Affect the Dose of Phenylephrine Needed to Prevent Spinal-Anesthesia Induced Hypotension in Cesarean Sections?

Authors:  Jing Qian; Lin Liu; Xiufeng Zheng; Fei Xiao
Journal:  Drug Des Devel Ther       Date:  2020-07-16       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.